Avidity Biosciences (RNA) Stock Forecast & Price Target

Compare

1,050 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RNA Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Avidity

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RNA Stock 12 Month Forecast

Average Price Target

$66.78

▲(44.08% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $66.78 with a high forecast of $96.00 and a low forecast of $49.00. The average price target represents a 44.08% change from the last price of $46.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$49.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,40.541538461538465,45.16307692307693,49.784615384615385,54.40615384615385,59.02769230769231,63.64923076923077,68.27076923076923,72.8923076923077,77.51384615384616,82.13538461538462,86.75692307692307,91.37846153846155,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,38.293846153846154,40.667692307692306,43.041538461538465,45.41538461538462,47.78923076923077,50.16307692307693,52.53692307692308,54.91076923076923,57.284615384615385,59.65846153846154,62.0323076923077,64.40615384615384,{"y":66.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,36.926153846153845,37.932307692307695,38.93846153846154,39.94461538461539,40.95076923076923,41.956923076923076,42.963076923076926,43.96923076923077,44.97538461538461,45.98153846153846,46.987692307692306,47.99384615384615,{"y":49,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$96.00

Average Price Target$66.78

Lowest Price Target$49.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Pickering

Bernstein

$50→$52

Buy

12.19%

Upside

Reiterated

08/15/25

Avidity Biosciences (RNA) Gets a Buy from BernsteinWe rate RNA Outperform. We raise our PT to $52, reflecting higher multiples on peak sales and adjustments to sales estimates.

Tazeen Ahmad

Bank of America Securities

$54

Buy

16.50%

Upside

Reiterated

08/14/25

Bank of America Securities Keeps Their Buy Rating on Avidity Biosciences (RNA)We reiterate our Buy with $54 PO.

Dex Genotek

TR | OpenAI - 4o

$50→$49

Hold

5.72%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Joseph Schwartz

Leerink Partners

$65

Buy

40.24%

Upside

Reiterated

08/12/25

Leerink Partners Remains a Buy on Avidity Biosciences (RNA)

Gavin Clark-Gartner

Evercore ISI

$70

Buy

51.02%

Upside

Reiterated

08/11/25

Avidity Biosciences (RNA) Gets a Buy from Evercore ISI

Ritu Baral

TD Cowen

$78

Buy

68.28%

Upside

Reiterated

08/08/25

Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial PositionWethink this AA pathway is low risk given multiple regulatory precedent approvals for current DMD drugs. In July 2024, RNA announced del-zota was granted breakthrough designation by FDA.

Joseph Stringer

Needham

$60

Buy

29.45%

Upside

Reiterated

08/08/25

Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating

Geoff Meacham

Citi

$75

Buy

61.81%

Upside

Reiterated

08/08/25

Citi Remains a Buy on Avidity Biosciences (RNA)

Gena Wang

Barclays

$59→$62

Buy

33.76%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Arcellx Inc (ACLX), Omada Health, Inc. (OMDA)

Ananda Ghosh

H.C. Wainwright

$68

Buy

46.71%

Upside

Reiterated

08/08/25

Promising Potential of Avidity Biosciences: Buy Rating Affirmed by Ananda GhoshValuation and Risks. Our price target of $68 is based on an equally weighted composite of: (a) $82/share, as a 25x multiple of taxed and diluted 2034 EPS of $9/share discounted back to and (b) an NPV discounted cash flow of $54/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in-line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.

Yanan Zhu

Wells Fargo

$70→$75

Buy

61.81%

Upside

Reiterated

08/08/25

Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position

Luca Issi

RBC Capital

$61

Buy

31.61%

Upside

Reiterated

08/08/25

RBC Capital Sticks to Their Buy Rating for Avidity Biosciences (RNA)

Corinne Johnson

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Eric Schmidt FCA

Cantor Fitzgerald

$96

Buy

107.12%

Upside

Reiterated

06/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Andy Chen

Wolfe Research

$55

Buy

18.66%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Pickering

Bernstein

$50→$52

Buy

12.19%

Upside

Reiterated

08/15/25

Avidity Biosciences (RNA) Gets a Buy from BernsteinWe rate RNA Outperform. We raise our PT to $52, reflecting higher multiples on peak sales and adjustments to sales estimates.

Tazeen Ahmad

Bank of America Securities

$54

Buy

16.50%

Upside

Reiterated

08/14/25

Bank of America Securities Keeps Their Buy Rating on Avidity Biosciences (RNA)We reiterate our Buy with $54 PO.

Dex Genotek

TR | OpenAI - 4o

$50→$49

Hold

5.72%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Joseph Schwartz

Leerink Partners

$65

Buy

40.24%

Upside

Reiterated

08/12/25

Leerink Partners Remains a Buy on Avidity Biosciences (RNA)

Gavin Clark-Gartner

Evercore ISI

$70

Buy

51.02%

Upside

Reiterated

08/11/25

Avidity Biosciences (RNA) Gets a Buy from Evercore ISI

Ritu Baral

TD Cowen

$78

Buy

68.28%

Upside

Reiterated

08/08/25

Joseph Stringer

Needham

$60

Buy

29.45%

Upside

Reiterated

08/08/25

Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating

Geoff Meacham

Citi

$75

Buy

61.81%

Upside

Reiterated

08/08/25

Citi Remains a Buy on Avidity Biosciences (RNA)

Gena Wang

Barclays

$59→$62

Buy

33.76%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Arcellx Inc (ACLX), Omada Health, Inc. (OMDA)

Ananda Ghosh

H.C. Wainwright

$68

Buy

46.71%

Upside

Reiterated

08/08/25

Yanan Zhu

Wells Fargo

$70→$75

Buy

61.81%

Upside

Reiterated

08/08/25

Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position

Luca Issi

RBC Capital

$61

Buy

31.61%

Upside

Reiterated

08/08/25

RBC Capital Sticks to Their Buy Rating for Avidity Biosciences (RNA)

Corinne Johnson

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Eric Schmidt FCA

Cantor Fitzgerald

$96

Buy

107.12%

Upside

Reiterated

06/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Andy Chen

Wolfe Research

$55

Buy

18.66%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avidity Biosciences

1 Month

xxx

Success Rate

14/25 ratings generated profit

Average Return

+4.86%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +4.86% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+15.38%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +15.38% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

15/22 ratings generated profit

Average Return

+109.99%

reiterated a buy rating 12 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +109.99% per trade.

2 Years

xxx

Success Rate

15/17 ratings generated profit

Average Return

+142.94%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +142.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNA Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RNA has received 38 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 66.78.

Each month's total comprises the sum of three months' worth of ratings.

RNA Financial Forecast

RNA Earnings Forecast

Next quarter’s earnings estimate for RNA is -$1.14 with a range of -$1.78 to -$0.61. The previous quarter’s EPS was -$1.21. RNA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Sales Forecast

Next quarter’s sales forecast for RNA is $1.95M with a range of $0.00 to $3.85M. The previous quarter’s sales results were $3.85M. RNA beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 66.78.

What is RNA’s upside potential, based on the analysts’ average price target?

Avidity Biosciences Inc has 44.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RNA a Buy, Sell or Hold?

Avidity Biosciences Inc has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is Avidity Biosciences Inc’s price target?

The average price target for Avidity Biosciences Inc is 66.78. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $96.00 ,the lowest forecast is $49.00. The average price target represents 44.08% Increase from the current price of $46.35.

What do analysts say about Avidity Biosciences Inc?

Avidity Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of RNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avidity Biosciences (RNA) Stock Forecast & Price Target

RNA Analyst Ratings

RNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avidity Biosciences

RNA Analyst Recommendation Trends

RNA Financial Forecast

RNA Earnings Forecast

RNA Sales Forecast

RNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts